ReviewNature reviews. Immunology2020
Cross-reactive memory T cells and herd immunity to SARS-CoV-2.
Review in Nature reviews. Immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 184 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
184 citing papers in PubMed, 1 synthesis or guideline pooled it, 279 citations in OpenAlex.
- Pooled it
- Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study.Scientific reports · 2024Trial
- Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.Nature communications · 2022Trial
- Characterization of SARS-CoV-2 and common cold coronavirus-specific T-cell responses in MIS-C and Kawasaki disease children.European journal of immunology · 2022Trial
- Immune signatures underlying post-acute COVID-19 lung sequelae.Science immunology · 2021Trial
- Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection.The Journal of clinical investigation · 2021Trial
- Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primates.EBioMedicine · 2026Article
- Serial vaccination expands and refines human CD4bioRxiv : the preprint server for biology · 2026Article
- Cellular Immune Response Induced by mRNA Vaccines Against SARS-CoV-2.Immunity, inflammation and disease · 2026Review
- Immune Priming and the Risk of COVID-19, Influenza, and Other Acute Respiratory Infections: Insights From an N3C Cohort.Influenza and other respiratory viruses · 2026Article
- Diagnostic performance evaluation of Elecsys anti-SARS-CoV-2 assay against RT-PCR for SARS-CoV-2 detection and surveillance in Ethiopian referral hospitals: cross-sectional study.Scientific reports · 2026Article
- Updated profiling of COVID-19 vaccine adverse events using VAERS case reports.Frontiers in pharmacology · 2026Article
- Broad and robust T cell immunity compensates the population immune barrier against antibody-escaping Omicron variants.Frontiers in immunology · 2026Article
- Heterologous immunity and antibody-dependent enhancement in respiratory virus infections.Molecular biology reports · 2025Review
- Development and Clinical Validation of a Skin Test for In Vivo Assessment of SARS-CoV-2 Specific T-Cell Immunity.Viruses · 2025Article
- Pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2 among female sex workers in Dakar, Senegal.Frontiers in public health · 2025Article
- Lung-resident SARS-CoV-2 peptide-specific immune responses in perfused 3D human lung explant models.Frontiers in bioengineering and biotechnology · 2025Article
- Prepandemic levels of cytokines and immunoglobulins and risk of SARS-CoV-2 infection and COVID-19 in the general population of Barcelona.Frontiers in public health · 2025Article
- The characterization of CD8Emerging microbes & infections · 2024Review
- Article
124 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Immunity is a multifaceted phenomenon. For T cell-mediated memory responses to SARS-CoV-2, it is relevant to consider their impact both on COVID-19 disease severity and on viral spread in a population. Here, we reflect on the immunological and epidemiological aspects and implications of pre-existing cross-reactive immune memory to SARS-CoV-2, which largely originates from previous exposure to circulating common cold coronaviruses. We propose four immunological scenarios for the impact of cross-reactive CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.